Trial Profile

DAREON-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obrixtamig (Primary) ; Atezolizumab; Carboplatin; Cisplatin; Durvalumab; Etoposide
Indications Carcinoma; Small cell lung cancer
Focus Adverse reactions
Acronyms DAREON-8
Sponsors Boehringer Ingelheim

29 Sep 2025 Status changed from recruiting to active, no longer recruiting.
08 Jul 2025 Planned number of patients changed from 60 to 47.
08 Jul 2025 Planned primary completion date changed from 20 Aug 2025 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com